The drug development pipeline for glioblastoma-A cross sectional assessment of the FDA Orphan Drug Product designation database.

ABSTRACT:

Background

Glioblastoma (GBM) is the most common malignant brain tumour among adult patients and represents an almost universally fatal disease. Novel therapies for GBM are being developed under the orphan drug legislation and the knowledge on the molecular makeup of this disease has been increasing rapidly. However, the clinical outcomes in GBM patients with currently available therapies are still dismal. An insight into the current drug development pipeline for GBM is therefore of particular interest.

Objectives

To provide a quantitative clinical-regulatory insight into the status of FDA orphan drug designations for compounds intended to treat GBM.

Methods

Quantitative cross-sectional analysis of the U.S. Food and Drug Administration Orphan Drug Product database bet

SUBMITTER: Johann P 

PROVIDER: S-EPMC8263276 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature